Table of Contents
Advances in Geriatrics
Volume 2014 (2014), Article ID 891780, 15 pages
http://dx.doi.org/10.1155/2014/891780
Review Article

Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment

Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany

Received 12 January 2014; Revised 15 May 2014; Accepted 29 May 2014; Published 18 June 2014

Academic Editor: Richard C. Dodel

Copyright © 2014 Piotr Lewczuk. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Hort, J. T. O'Brien, G. Gainotti et al., “EFNS guidelines for the diagnosis and management of Alzheimer’s disease,” European Journal of Neurology, vol. 17, no. 10, pp. 1236–1248, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Thies and L. Bleiler, “2011 Alzheimer’s disease facts and figures,” Alzheimer’s and Dementia, vol. 7, no. 2, pp. 208–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. Alzheimer's Association, “2010 Alzheimer's disease facts and figures,” Alzheimer's & Dementia: The Journal of the Alzheimer's Association, vol. 6, no. 2, pp. 158–194, 2010. View at Publisher · View at Google Scholar
  4. K. Blennow, M. J. de Leon, and H. Zetterberg, “Alzheimer’s disease,” The Lancet, vol. 368, no. 9533, pp. 387–403, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. J. de Leon, J. Golomb, A. E. George et al., “The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation,” American Journal of Neuroradiology, vol. 14, no. 4, pp. 897–906, 1993. View at Google Scholar · View at Scopus
  6. H. Braak and E. Braak, “Frequency of stages of Alzheimer-related lesions in different age categories,” Neurobiology of Aging, vol. 18, no. 4, pp. 351–357, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. de Leon, A. Convit, O. T. Wolf et al., “Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET),” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10966–10971, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Price and J. C. Morris, “Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease,” Annals of Neurology, vol. 45, no. 3, pp. 358–368, 1999. View at Google Scholar
  9. B. Dubois, H. H. Feldman, C. Jacova et al., “Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria,” Lancet Neurology, vol. 6, no. 8, pp. 734–746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. R. C. Petersen, P. S. Aisen, L. A. Beckett et al., “Alzheimer’s disease neuroimaging initiative (ADNI): clinical characterization,” Neurology, vol. 74, no. 3, pp. 201–209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. M. Torpy, C. Lynm, and R. M. Glass, “JAMA patient page. Mild cognitive impairment,” The Journal of the American Medical Association, vol. 302, no. 4, p. 452, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. D. Aluise, R. A. Sowell, and D. A. Butterfield, “Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer’s disease,” Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1782, no. 10, pp. 549–558, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. G. Beach, S. E. Monsell, L. E. Phillips, and W. Kukull, “Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010,” Journal of Neuropathology and Experimental Neurology, vol. 71, no. 4, pp. 266–273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Braak and E. Braak, “Neuropathological stageing of Alzheimer-related changes,” Acta Neuropathologica, vol. 82, no. 4, pp. 239–259, 1991. View at Google Scholar · View at Scopus
  15. P. Lewczuk, G. Beck, O. Ganslandt et al., “International quality control survey of neurochemical dementia diagnostics,” Neuroscience Letters, vol. 409, no. 1, pp. 1–4, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Reiber, “Flow rate of cerebrospinal fluid (CSF)—a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases,” Journal of the Neurological Sciences, vol. 122, no. 2, pp. 189–203, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Reiber and J. B. Peter, “Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs,” Journal of the Neurological Sciences, vol. 184, no. 2, pp. 101–122, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Hampel, H. U. Kötter, F. Padberg, D. A. Körschenhausen, and H. Möller, “Oligoclonal bands and blood-cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis,” Alzheimer Disease and Associated Disorders, vol. 13, no. 1, pp. 9–19, 1999. View at Google Scholar · View at Scopus
  19. R. Zimmermann, G. Beck, S. Knispel et al., “Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics,” Journal of Alzheimer’s Disease, vol. 19, no. 4, pp. 1199–1203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Zetterberg, K. Tullhög, O. Hansson, L. Minthon, E. Londos, and K. Blennow, “Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients,” European Neurology, vol. 63, no. 6, pp. 326–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Peskind, A. Nordberg, T. Darreh-Shori, and H. Soininen, “Safety of lumbar puncture procedures in patients with Alzheimer’s disease,” Current Alzheimer Research, vol. 6, no. 3, pp. 290–292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Alcolea, P. Martinez-Lage, A. Izagirre et al., “Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain,” Journal of Alzheimer's Disease, vol. 39, pp. 719–726, 2014. View at Google Scholar
  23. J. Popp, M. Riad, K. Freymann, and F. Jessen, “Diagnostic lumbar puncture performed in the outpatient setting of a memory clinic: frequency and risk factors of post-lumbar puncture headache,” Nervenarzt, vol. 78, no. 5, pp. 547–551, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Kang, H.-G. Lemaire, and A. Unterbeck, “The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor,” Nature, vol. 325, no. 6106, pp. 733–736, 1987. View at Google Scholar · View at Scopus
  25. P. K. Panegyres, “The amyloid precursor protein gene: a neuropeptide gene with diverse functions in the central nervous system,” Neuropeptides, vol. 31, no. 6, pp. 523–535, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Citron, T. S. Diehl, G. Gordon, A. L. Biere, P. Seubert, and D. J. Selkoe, “Evidence that the 42- and 40-amino acid forms of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 23, pp. 13170–13175, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. H.-W. Klafki, D. Abramowski, R. Swoboda, P. A. Paganetti, and M. Staufenbiel, “The carboxyl termini of β-amyloid peptides 1-40 and 1-42 are generated by distinct γ-secretase activities,” Journal of Biological Chemistry, vol. 271, no. 45, pp. 28655–28659, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. S. F. Lichtenthaler, D. Beher, H. S. Grimm et al., “The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1365–1370, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Jang, F. T. Arce, S. Ramachandran et al., “Truncated β-amyloid peptide channels provide an alternative mechanism for Alzheimer’s Disease and Down syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 14, pp. 6538–6543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. C. M. Carlsson, “Type 2 diabetes mellitus, dyslipidemia, and Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 20, no. 3, pp. 711–722, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Taubes, “Insulin insults may spur Alzheimer’s disease,” Science, vol. 301, no. 5629, pp. 40–41, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. G. S. Watson, E. R. Peskind, S. Asthana et al., “Insulin increases CSF Aβ42 levels in normal older adults,” Neurology, vol. 60, no. 12, pp. 1899–1903, 2003. View at Google Scholar · View at Scopus
  33. M. Karczewska-Kupczewska, N. Lelental, A. Adamska et al., “The influence of insulin infusion on the metabolism of amyloid b peptides in plasma,” Alzheimer’s and Dementia, vol. 9, no. 4, pp. 400–405, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Lewczuk, H. Esselmann, M. Otto et al., “Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau,” Neurobiology of Aging, vol. 25, no. 3, pp. 273–281, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. L. M. Shaw, H. Vanderstichele, M. Knapik-Czajka et al., “Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI,” Acta Neuropathologica, vol. 121, no. 5, pp. 597–609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Lewczuk and J. Kornhuber, “Neurochemical dementia diagnostics in Alzheimer’s disease: where are we now and where are we going?” Expert Review of Proteomics, vol. 8, no. 4, pp. 447–458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Motter, C. Vigo-Pelfrey, D. Kholodenko et al., “Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease,” Annals of Neurology, vol. 38, no. 4, pp. 643–648, 1995. View at Google Scholar · View at Scopus
  38. J. Wiltfang, H. Esselmann, A. Smirnov et al., “β-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease,” Annals of Neurology, vol. 54, no. 2, pp. 263–267, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Sjögren, M. Gisslén, E. Vanmechelen, and K. Blennow, “Low cerebrospinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment,” Neuroscience Letters, vol. 314, no. 1-2, pp. 33–36, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. P. E. Spies, M. M. Verbeek, T. Van Groen, and J. A. H. R. Claassen, “Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease,” Frontiers in Bioscience, vol. 17, no. 6, pp. 2024–2034, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Lewczuk, H. Esselmann, M. Meyer et al., “The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Aβ peptide,” Rapid Communications in Mass Spectrometry, vol. 17, no. 12, pp. 1291–1296, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Tapiola, H. Soininen, and T. Pirttilä, “CSF tau and Aβ42 levels in patients with Down's syndrome,” Neurology, vol. 56, no. 7, p. 979, 2001. View at Google Scholar · View at Scopus
  43. P. Lewczuk, H. Kamrowski-Kruck, O. Peters et al., “Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study,” Molecular Psychiatry, vol. 15, no. 2, pp. 138–145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Lewczuk, J. Popp, N. Lelental et al., “Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 28, no. 1, pp. 119–125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Pérez, L. Morelli, J. C. Cresto, and E. M. Castaño, “Degradation of soluble amyloid β-peptides 1–40, 1–42, and the Dutch variant 1–40Q by insulin degrading enzyme from Alzheimer disease and control brains,” Neurochemical Research, vol. 25, no. 2, pp. 247–255, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. M. M. Wilhelmus, I. Otte-Höller, J. J. J. Van Triel et al., “Lipoprotein receptor-related protein-1 mediates amyloid-β-mediated cell death of cerebrovascular cells,” American Journal of Pathology, vol. 171, no. 6, pp. 1989–1999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Deane, R. D. Bell, A. Sagare, and B. V. Zlokovic, “Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease,” CNS and Neurological Disorders-Drug Targets, vol. 8, no. 1, pp. 16–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Lewczuk, J. Kornhuber, E. Vanmechelen et al., “Amyloid β peptides in plasma in early diagnosis of Alzheimer’s disease: a multicenter study with multiplexing,” Experimental Neurology, vol. 223, no. 2, pp. 366–370, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. N. R. Graff-Radford, J. E. Crook, J. Lucas et al., “Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease,” Archives of Neurology, vol. 64, no. 3, pp. 354–362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. van Oijen, A. Hofman, H. D. Soares, P. J. Koudstaal, and M. M. Breteler, “Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study,” Lancet Neurology, vol. 5, no. 8, pp. 655–660, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Wang-Dietrich, S. A. Funke, K. Kühbach et al., “The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 34, no. 4, pp. 985–994, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Hulstaert, K. Blennow, A. Ivanoiu et al., “Improved discrimination of AD patients using β-amyloid((1-42)) and tau levels in CSF,” Neurology, vol. 52, no. 8, pp. 1555–1562, 1999. View at Google Scholar · View at Scopus
  53. D. Galasko, L. Chang, R. Motter et al., “High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype,” Archives of Neurology, vol. 55, no. 7, pp. 937–945, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Buée, T. Bussière, V. Buée-Scherrer, A. Delacourte, and P. R. Hof, “Tau protein isoforms, phosphorylation and role in neurodegenerative disorders,” Brain Research Reviews, vol. 33, no. 1, pp. 95–130, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Mandelkow, M. Von Bergen, J. Biernat, and E. Mandelkow, “Structural principles of tau and the paired helical filaments of Alzheimer’s disease,” Brain Pathology, vol. 17, no. 1, pp. 83–90, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. N. J. Cairns, V. M.-Y. Lee, and J. Q. Trojanowski, “The cytoskeleton in neurodegenerative diseases,” Journal of Pathology, vol. 204, no. 4, pp. 438–449, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Shahani and R. Brandt, “Functions and malfunctions of the tau proteins,” Cellular and Molecular Life Sciences, vol. 59, no. 10, pp. 1668–1680, 2002. View at Google Scholar · View at Scopus
  58. I. Morales, J. M. Jimenez, M. Mancilla, and R. B. Maccioni, “Tau oligomers and fibrils induce activation of microglial cells,” Journal of Alzheimer's Disease, vol. 37, no. 4, pp. 849–856, 2013. View at Google Scholar
  59. A. Takashima, “Tauopathies and tau oligomers,” Journal of Alzheimer's Disease, vol. 37, no. 3, pp. 565–568, 2013. View at Google Scholar
  60. M. Mawal-Dewan, J. Henley, A. Van De Voorde, J. Q. Trojanowski, and V. M.-Y. Lee, “The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases,” Journal of Biological Chemistry, vol. 269, no. 49, pp. 30981–30987, 1994. View at Google Scholar · View at Scopus
  61. H. Rosner, M. Rebhan, G. Vacun, and E. Vanmechelen, “Developmental expression of tau proteins in the chicken and rat brain: rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms,” International Journal of Developmental Neuroscience, vol. 13, no. 6, pp. 607–617, 1995. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Sunderland, G. Linker, N. Mirza et al., “Decreased β-Amyloid1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients with Alzheimer Disease,” Journal of the American Medical Association, vol. 289, no. 16, pp. 2094–2103, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Hesse, L. Rosengren, N. Andreasen et al., “Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke,” Neuroscience Letters, vol. 297, no. 3, pp. 187–190, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Otto, J. Wiltfang, H. Tumani et al., “Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease,” Neuroscience Letters, vol. 225, no. 3, pp. 210–212, 1997. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Iqbal, I. Grundke-Iqbal, T. Zaidi et al., “Defective brain microtubule assembly in Alzheimer’s disease,” The Lancet, vol. 2, no. 8504, pp. 421–426, 1986. View at Publisher · View at Google Scholar · View at Scopus
  66. I. Grundke-Iqbal, K. Iqbal, and Y.-C. Tung, “Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 13, pp. 44913–4917, 1986. View at Google Scholar · View at Scopus
  67. K. Blennow, E. Vanmechelen, and H. Hampel, “CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease,” Molecular Neurobiology, vol. 24, no. 1–3, pp. 87–97, 2001. View at Google Scholar · View at Scopus
  68. P. Lewczuk, H. Esselmann, M. Bibl et al., “Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease: original data and review of the literature,” Journal of Molecular Neuroscience, vol. 23, no. 1-2, pp. 115–122, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Vanmechelen, E. Van Kerschaver, K. Blennow et al., “CSF-Phospho-tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies,” in Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, K. Iqbal, S. S. Sisodia, and B. Winblad, Eds., pp. 285–291, John Wiley and Sons, Chichester, UK, 2001. View at Google Scholar
  70. L. Parnetti, A. Lanari, S. Amici, V. Gallai, E. Vanmechelen, and F. Hulstaert, “CSF phosphorylated tau is a possible marker for discriminating Alzheimer’s disease from dementia with Lewy bodies,” Neurological Sciences, vol. 22, no. 1, pp. 77–78, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. N. Itoh, H. Arai, K. Urakami et al., “Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease,” Annals of Neurology, vol. 50, no. 2, pp. 150–156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Hampel, K. Buerger, R. Kohnken et al., “Tracking of Alzheimer’s disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231,” Annals of Neurology, vol. 49, no. 4, pp. 545–546, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Arai, K. Ishiguro, H. Ohno et al., “CSF phosphorylated tau protein and mild cognitive impairment: a prospective study,” Experimental Neurology, vol. 166, no. 1, pp. 201–203, 2000. View at Publisher · View at Google Scholar · View at Scopus
  74. Z. F. Wang, H. L. Li, X. C. Li et al., “Effects of endogenous β-amyloid overproduction on tau phosphorylation in cell culture,” Journal of Neurochemistry, vol. 98, no. 4, pp. 1167–1175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Grueninger, B. Bohrmann, C. Czech et al., “Phosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice,” Neurobiology of Disease, vol. 37, no. 2, pp. 294–306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. H. C. Huang and Z. F. Jiang, “Accumulated amyloid-β peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 16, no. 1, pp. 15–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Mudher and S. Lovestone, “Alzheimer’s disease-do tauists and baptists finally shake hands?” Trends in Neurosciences, vol. 25, no. 1, pp. 22–26, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Lewczuk, R. Zimmermann, J. Wiltfang, and J. Kornhuber, “Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers,” Journal of Neural Transmission, vol. 116, no. 9, pp. 1163–1167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Slaets, N. Le Bastard, J. Martin et al., “Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels,” Journal of Alzheimer’s Disease, vol. 36, no. 4, pp. 759–767, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. M. S. Albert, S. T. DeKosky, D. Dickson et al., “The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,” Alzheimer’s and Dementia, vol. 7, no. 3, pp. 270–279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. C. R. Jack Jr., M. S. Albert, D. S. Knopman et al., “Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,” Alzheimer’s and Dementia, vol. 7, no. 3, pp. 257–262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. G. M. McKhann, “Changing concepts of Alzheimer disease,” Journal of the American Medical Association, vol. 305, no. 23, pp. 2458–2459, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. R. A. Sperling, P. S. Aisen, L. A. Beckett et al., “Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,” Alzheimer’s and Dementia, vol. 7, no. 3, pp. 280–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. S3-Leitlinie, “Demenzen”, 2009 http://www.dggpp.de/documents/s3-leitlinie-demenz-kf.pdf.
  85. J. C. Morris, K. Blennow, L. Froelich et al., “Harmonized diagnostic criteria for Alzheimer's disease: recommendations,” Journal of Internal Medicine, vol. 275, no. 3, pp. 204–213, 2014. View at Publisher · View at Google Scholar
  86. G. M. McKhann, D. S. Knopman, H. Chertkow et al., “The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,” Alzheimer’s and Dementia, vol. 7, no. 3, pp. 263–269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study,” Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. N. Mattsson, H. Zetterberg, O. Hansson et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Zetterberg, L. Wahlund, and K. Blennow, “Cerebrospinal fluid markers for prediction of Alzheimer’s disease,” Neuroscience Letters, vol. 352, no. 1, pp. 67–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Lewczuk, J. Kornhuber, H. Vanderstichele et al., “Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study,” Neurobiology of Aging, vol. 29, no. 6, pp. 812–818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. I. A. van Rossum, S. Vos, R. Handels, and P. J. Visser, “Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design,” Journal of Alzheimer’s Disease, vol. 20, no. 3, pp. 881–891, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. C. R. Jack Jr., D. S. Knopman, W. J. Jagust et al., “Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade,” The Lancet Neurology, vol. 9, no. 1, pp. 119–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. D. S. Knopman, J. E. Parisi, A. Salviati et al., “Neuropathology of cognitively normal elderly,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 11, pp. 1087–1095, 2003. View at Google Scholar · View at Scopus
  94. C. Ballatore, V. M.-Y. Lee, and J. Q. Trojanowski, “Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders,” Nature Reviews Neuroscience, vol. 8, no. 9, pp. 663–672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Vemuri, H. J. Wiste, S. D. Weigand et al., “MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations,” Neurology, vol. 73, no. 4, pp. 287–293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. E. S. Musiek and D. M. Holtzman, “Origins of Alzheimer’s disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement,” Current Opinion in Neurology, vol. 25, no. 6, pp. 715–720, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. H. Struyfs, J. L. Molinuevo, J. J. Martin, P. P. De Deyn, and S. Engelborghs, “Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls,” Journal of Alzheimer's Disease, 2014. View at Google Scholar
  98. P. Scheltens and K. Rockwood, “How golden is the gold standard of neuropathology in dementia?” Alzheimer’s and Dementia, vol. 7, no. 4, pp. 486–489, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. R. Zimmermann, E. Huber, C. Schamber et al., “Plasma concentrations of the amyloid-β peptides in young volunteers: the influence of the APOE genotype,” Journal of Alzheimer's Disease, vol. 40, no. 4, pp. 1055–1060, 2014. View at Google Scholar
  100. J. Popp, P. Lewczuk, I. Frommann et al., “Cerebrospinal fluid markers for alzheimer’s disease over the lifespan: effects of age and the APOEε4 genotype,” Journal of Alzheimer’s Disease, vol. 22, no. 2, pp. 459–468, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. W. Khan, V. Giampietro, C. Ginestet et al., “No differences in hippocampal volume between carriers and non-carriers of the ApoE epsilon4 and epsilon2 alleles in young healthy adolescents,” Journal of Alzheimer's Disease, vol. 40, no. 1, pp. 37–43, 2014. View at Google Scholar
  102. R. J. Bateman, C. Xiong, T. L. S. Benzinger et al., “Clinical and biomarker changes in dominantly inherited Alzheimer’s disease,” New England Journal of Medicine, vol. 367, no. 9, pp. 795–804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. K. A. Johnson, N. C. Fox, R. A. Sperling, and W. E. Klunk, “Brain imaging in Alzheimer disease,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 4, Article ID a006213, 2012. View at Google Scholar · View at Scopus
  104. L. Mosconi, H. T. Wai, A. Pupi et al., “18F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer’s disease,” Journal of Nuclear Medicine, vol. 48, no. 7, pp. 1129–1134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. V. Kepe, M. C. Moghbel, B. Långströmd et al., “Amyloid-β positron emission tomography imaging probes: a critical review,” Journal of Alzheimer’s Disease, vol. 36, no. 4, pp. 613–631, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Vos, I. van Rossum, L. Burns et al., “Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI,” Neurobiology of Aging, vol. 33, no. 10, pp. 2272–2281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Brys, L. Glodzik, L. Mosconi et al., “Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 16, no. 2, pp. 351–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. N. S. M. Schoonenboom, C. Mulder, H. Vanderstichele et al., “Effects of processing and storage conditions on amyloid β (1–42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice,” Clinical Chemistry, vol. 51, no. 1, pp. 189–195, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Jensen, T. Hartmann, B. Engvall et al., “Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems,” Molecular Medicine, vol. 6, no. 4, pp. 291–302, 2000. View at Google Scholar · View at Scopus
  110. H. Vanderstichele, E. Van Kerschaver, C. Hesse et al., “Standardization of measurement of β-amyloid((1-42)) in cerebrospinal fluid and plasma,” Amyloid, vol. 7, no. 4, pp. 245–258, 2000. View at Google Scholar · View at Scopus
  111. H. Vanderstichele, M. Bibl, S. Engelborghs et al., “Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative,” Alzheimer’s and Dementia, vol. 8, no. 1, pp. 65–73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. R. J. Bateman, E. R. Siemers, K. G. Mawuenyega et al., “A γ-secretase inhibitor decreases amyloid-β production in the central nervous system,” Annals of Neurology, vol. 66, no. 1, pp. 48–54, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Bjerke, E. Portelius, L. Minthon et al., “Confounding factors influencing amyloid beta concentration in cerebrospinal fluid,” International Journal of Alzheimer’s Disease, Article ID 986310, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Perret-Liaudet, M. Pelpel, S. Lehmann, S. Schraen, H. Vanderstichele, and I. Quadrio, “Sampling tube, a critical factor in Alzheimer disease biomarker standardization,” in Proceedings of the International Conference on Alzheimer's Disease, Honolulu, Hawaii, USA, July 2010.
  115. R. Zimmermann, N. Lelental, O. Ganslandt, J. M. Maler, J. Kornhuber, and P. Lewczuk, “Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics,” Journal of Alzheimer’s Disease, vol. 25, no. 4, pp. 739–745, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. “Richtlinie der Bundesärztekammer zur qulitätssicherung laboratoriumsmedizinischen Untersuchungen,” Deutsches Ärzteblatt, vol. 105, pp. A341–A355, 2008.
  117. J. Waedt, M. Kleinow, J. Kornhuber, and P. Lewczuk, “Neurochemical dementia diagnostics for Alzheimers disease and other dementias: an ISO 15189 perspective,” Biomarkers in Medicine, vol. 6, no. 5, pp. 685–690, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. N. A. Verwey, W. M. Van Der Flier, K. Blennow et al., “A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease,” Annals of Clinical Biochemistry, vol. 46, no. 3, pp. 235–240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. M. C. Carrillo, K. Blennow, H. Soares et al., “Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium,” Alzheimer’s and Dementia, vol. 9, no. 2, pp. 137–140, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. N. Mattsson, U. Andreasson, S. Persson et al., “The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers,” Alzheimer’s and Dementia, vol. 7, no. 4, pp. 386.e6–395.e6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. Consensus report of the Working Group, “Molecular and biochemical markers of Alzheimer's disease,” Neurobiology of Aging, vol. 19, no. 2, pp. 109–116, 1998. View at Publisher · View at Google Scholar
  122. EMA, Qualification Opinion of Alzheimer's Disease Novel Methodologies/biomarkers for BMS-708163, 2011.
  123. J. Randall, E. Mörtberg, G. K. Provuncher et al., “Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study,” Resuscitation, vol. 84, no. 3, pp. 351–356, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. H. Reiber, “Dynamics of brain-derived proteins in cerebrospinal fluid,” Clinica Chimica Acta, vol. 310, no. 2, pp. 173–186, 2001. View at Publisher · View at Google Scholar · View at Scopus
  125. K. Felgenhauer and W. Beuche, Labordiagnostik Neurologischer Erkrankungen: Liquoranalytik und -Zytologie, Diagnose- und Processmarker, Thieme, Stuttgart, Germany, 1999.
  126. R. B. DeMattos, K. R. Bales, D. J. Cummins, J. Dodart, S. M. Paul, and D. M. Holtzman, “Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8850–8855, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. R. B. DeMattos, K. R. Bales, D. J. Cummins, S. M. Paul, and D. M. Holtzman, “Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease,” Science, vol. 295, no. 5563, pp. 2264–2267, 2002. View at Publisher · View at Google Scholar · View at Scopus
  128. S. D. Preston, P. V. Steart, A. Wilkinson, J. A. R. Nicoll, and R. O. Weller, “Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid β from the human brain,” Neuropathology and Applied Neurobiology, vol. 29, no. 2, pp. 106–117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Di Luca, L. Pastorino, A. Bianchetti et al., “Differential level of platelet amyloid β precursor protein isoforms: an early marker for Alzheimer disease,” Archives of Neurology, vol. 55, no. 9, pp. 1195–1200, 1998. View at Publisher · View at Google Scholar · View at Scopus
  130. Y.-M. Kuo, T. A. Kokjohn, M. D. Watson et al., “Elevated Aβ42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AβPP metabolism,” American Journal of Pathology, vol. 156, no. 3, pp. 797–805, 2000. View at Google Scholar · View at Scopus
  131. P. Lewczuk, H. Esselmann, M. Bibl et al., “Electrophoretic separation of amyloid β peptides in plasma,” Electrophoresis, vol. 25, no. 20, pp. 3336–3343, 2004. View at Publisher · View at Google Scholar · View at Scopus
  132. J. M. Maler, H. Klafki, S. Paul et al., “Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Aβ species,” Proteomics, vol. 7, no. 20, pp. 3815–3820, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. R. Mayeux, L. S. Honig, M.-X. Tang et al., “Plasma A40 and A42 and Alzheimer’s disease: relation to age, mortality, and risk,” Neurology, vol. 61, no. 9, pp. 1185–1190, 2003. View at Google Scholar · View at Scopus
  134. S. H. Freeman, S. Raju, B. T. Hyman, M. P. Frosch, and M. C. Irizarry, “Plasma Aβ levels do not reflect brain Aβ levels,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 4, pp. 264–271, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. V. Giedraitis, J. Sundelöf, M. C. Irizarry et al., “The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer’s disease,” Neuroscience Letters, vol. 427, no. 3, pp. 127–131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. X. Sun, D. C. Steffens, R. Au et al., “Amyloid-associated depression: a prodromal depression of Alzheimer disease?” Archives of General Psychiatry, vol. 65, no. 5, pp. 542–550, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. R. L. Ownby, E. Crocco, A. Acevedo, V. John, and D. Loewenstein, “Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis,” Archives of General Psychiatry, vol. 63, no. 5, pp. 530–538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  138. O. Hansson, H. Zetterberg, E. Vanmechelen et al., “Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment,” Neurobiology of Aging, vol. 31, no. 3, pp. 357–367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. A. Koyama, O. I. Okereke, T. Yang, D. Blacker, D. J. Selkoe, and F. Grodstein, “Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis,” Archives of Neurology, vol. 69, no. 7, pp. 824–831, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. A. D. Watt, K. A. Perez, A. R. Rembach, C. L. Masters, V. L. Villemagne, and K. J. Barnham, “Variability in blood-based amyloid-β assays: the need for consensus on pre-analytical processing,” Journal of Alzheimer’s Disease, vol. 30, no. 2, pp. 323–336, 2012. View at Publisher · View at Google Scholar · View at Scopus